Biolingus

Biolingus is pioneering a novel drug delivery platform focused on the sublingual (under-the-tongue) administration of large molecule drugs, including peptides, proteins, and vaccines. Its core technology is designed to protect biologics from degradation in the gut and facilitate absorption directly into the bloodstream via the oral mucosa, potentially eliminating the need for painful and costly injections. The company is advancing a pipeline of internal and partnered programs, targeting significant markets in diabetes, obesity, and immunology. As a private, pre-revenue entity, Biolingus's success hinges on validating its platform in clinical trials and securing strategic partnerships to fund development and commercialization.

Proprietary sublingual (under-the-tongue) delivery platform utilizing formulation and permeation enhancement technologies to enable the oral administration of biologics (peptides, proteins, antibodies) and vaccines via fast-dissolving tablets/films.

Biolingus competes in the oral biologics space with companies using various technologies, including enteric coatings and GI-targeted permeation enhancers (e.g., Oramed, Entera Bio). Its sublingual approach is a key differentiator but is also pursued by others. The competitive intensity is high, with success hinging on demonstrating superior bioavailability, stability, and patient convenience.